Stifel confirms its buy recommendation on the stock with an unchanged target price of €75 after its quarterly sales figures.

The analyst believes that Equasens had a good Q1, with organic growth of 5.9%, which should help the company regain some of the confidence lost in the investment community.

Stifel expects organic growth to accelerate gradually this year, which should help improve the company's profitability despite continued investment.

At 9.4x 2025E EBITDA, we believe Equasens is materially undervalued given that its momentum should improve in 2025, the broker said.


Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are provided solely as a decision-making aid for investors. Cercle Finance cannot be held liable, directly or indirectly, for the use of such information and analyses by readers. Anyone who is not an expert in the field should consult a professional advisor before investing. This information is provided for informational purposes only and does not constitute an offer to sell or a solicitation to buy.